16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
July 2025 in “International Journal of Trichology” Oral tofacitinib may effectively regrow hair in children with alopecia areata unresponsive to other treatments.
April 2016 in “Journal of Investigative Dermatology” MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
9 citations
,
May 2013 in “JAMA Dermatology” A woman's hair turned white after taking a cancer drug called dasatinib.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
54 citations
,
September 2012 in “Acta ophthalmologica” Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
April 2025 in “Scientific Reports” Astragaloside A may help fight lung cancer by targeting specific proteins.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
May 2023 in “Blood cancer discovery” Finasteride reduces AML cell growth by inhibiting androgen receptors.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
May 2018 in “Dermatologic Surgery” 70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.